Georgia's Online Cancer Information Center

Bladder Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Bladder Cancer
Cancer Type = Bladder Cancer
There are currently 15 active Bladder Cancer clinical trials in Georgia.
1.
A Beta-only IL-2 ImmunoTherapY Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
2.
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Cancer Type
Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Unknown Primary
NCT ID
NCT06120075
Protocol IDs
ARC-27
NCI-2024-03901
Treatment Sites (1)
3.
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT04879329
Protocol IDs
RC48G001
NCI-2022-03375
2022-500030-28
2022-500030-28-01
C5731002
KEYNOTE-D78
MK-3475-D78
RC48 G001
4.
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04919512
Protocol IDs
CR109044
NCI-2022-05645
17000139BLC2002
2020-005565-13
Treatment Sites (1)
5.
Blue Light Cystoscopy With Cysview® Registry
Cancer Type
Bladder Cancer
NCT ID
NCT02660645
Protocol IDs
BLCCR-001
NCI-2018-00299
6.
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04878029
Protocol IDs
WINSHIP5259-21
NCI-2021-01365
STUDY00002329
7.
NCORP Trial
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCT ID
NCT05366881
Protocol IDs
Adela-EDMRD-001
NCI-2022-04272
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
9.
Enfortumab Vedotin plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Cancer Type
Bladder Cancer
NCT ID
NCT05756569
Protocol IDs
WINSHIP5742-22
NCI-2023-00104
STUDY00005143
Treatment Sites (1)
10.
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04752722
Protocol IDs
EG-70-101
NCI-2021-12422
11.
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04452591
Protocol IDs
CG3002S
NCI-2021-01691
12.
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT06632951
Protocol IDs
M25-204
NCI-2024-10299
2024-515506-11-00
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
13.
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type
Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer
NCT ID
NCT03866382
Protocol IDs
A031702
A031702
NCI-2019-01266
14.
NCORP Trial
Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy after Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT05987241
Protocol IDs
A032103
A032103
NCI-2023-05980
Treatment Sites (6)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
15.
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT06510374
Protocol IDs
000423
NCI-2025-01046
U1111-1284-0685
Treatment Sites (1)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169